VNDA — Vanda Pharmaceuticals Inc.

Is VNDA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Vanda Pharmaceuticals Inc. (VNDA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.81. The rating moved from Overbought to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Vanda Pharmaceuticals Inc. (VNDA) is a small‑cap specialty pharma with a concentrated revenue base and a development pipeline that offers optional upside but carries typical biotech clinical and regulatory risk. Near‑term performance will be driven by product sales trends, any upcoming clinical readouts or business development activity, and financing flexibility; broader sector flows toward large‑cap pharma may limit near‑term investor interest. Given limited public financial detail in the provided data, the equity appears fairly valued for now absent a clear near‑term catalyst, while downside remains if revenue or pipeline events disappoint.

Key factors

  • Revenue concentration around a small number of marketed products (notably sleep disorder franchise) with modest but stable cash flow generation
  • Pipeline assets provide upside optionality but have mixed clinical/development risk and uncertain near‑term catalysts
  • Limited public financial disclosure in the provided data increases uncertainty on cash runway and need for external financing
  • Sector flows favoring large‑cap pharma reduce investor appetite for smaller, development‑stage biotechs in the near term
  • Regulatory readthroughs in adjacent therapeutic areas (e.g., increased at‑home treatments) could create commercial opportunities if pipeline assets align
  • Potential for business development or licensing transactions to meaningfully change outlook given company size

Risks

  • High dependence on a small set of products — any sales decline, loss of exclusivity, or reimbursement pressure would materially hit revenue
  • Clinical or regulatory setbacks for pipeline programs could erode value quickly
  • Capital markets/financing risk: need for equity or convertible financing could lead to dilution
  • Competitive pressures from larger pharma entrants and generics/alternative therapies in sleep and neuroscience markets
  • Low trading liquidity and small market cap can amplify volatility and downside in risk‑off periods
  • Macroeconomic or sector rotations favoring large, defensive pharma reduce relative demand for VNDA shares

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for VNDA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.